Results 11 to 20 of about 38,724 (265)
The Clinical Significance of CD73 in Cancer
International Journal of Molecular Sciences, 2023 The search for new and effective treatment targets for cancer immunotherapy is an ongoing challenge. Alongside the more established inhibitory immune checkpoints, a novel potential target is CD73. As one of the key enzymes in the purinergic signalling pathway CD73 is responsible for the generation of immune suppressive adenosine. The expression of CD73
Eva Tolosa +2 more
exaly +4 more sources
The CD73 immune checkpoint promotes tumor cell metabolic fitness
eLife, 2023 CD73 is an ectonucleotidase overexpressed on tumor cells that suppresses anti-tumor immunity. Accordingly, several CD73 inhibitors are currently being evaluated in the clinic, including in large randomized clinical trials.
David Allard +6 more
doaj +2 more sources
Scientific ReportsCD73 is a cell-surface ectoenzyme that hydrolyzes the conversion of extracellular adenosine monophosphate to adenosine, which in turn can promote resistance to immune checkpoint blockade therapy.
Kyung-Ho Jung +6 more
doaj +2 more sources
CD73 is associated with glycolysis related metabolic programs and CD8+ T cell suppression in pancreatic ductal adenocarcinoma [PDF]
Frontiers in ImmunologyCD73 is an enzyme that generates extracellular adenosine and has been implicated in tumor-associated immune suppression, but its biological and clinical significance in pancreatic ductal adenocarcinoma (PDAC) remains incompletely understood.
Eriko Katsuta +8 more
doaj +2 more sources
CD39 and CD73 in immunity and inflammation [PDF]
Trends in Molecular Medicine, 2013 The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced ...
Pal Pacher, Luca Antonioli
exaly +4 more sources
CD73 Dysregulates Monocyte Anti-Tumor Activity in Multiple Myeloma
Cancer Management and Research, 2023 Lin Zhou,1,* XiaoLan Liu,2,* Tao Guan,2 HaiLing Xu,1 Fang Wei1 1Department of Hematology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 2Shanxi Key Laboratory of Precise and Diagnosis and Therapy of
Zhou L, Liu X, Guan T, Xu H, Wei F
doaj +1 more source
CD73 in Autoimmune Arthritis [PDF]
Receptors & Clinical Investigation, 2015 Abstract Adenosine is a potent anti-inflammatory molecule that plays an important role in many diseases. Extracellular levels of adenosine are determined by a combination of membrane transporters and ecto-nucleotidases such as CD73. Therapeutic targeting of the adenosinergic pathway, such as administration of adenosine receptor agonists, could be a ...
Pavel Chrobak, John Stagg
core +3 more sources
Advanced Science, 2023 CD73, a cell surface‐bound nucleotidase, facilitates extracellular adenosine formation by hydrolyzing 5′‐AMP to adenosine. Several studies have shown that CD73 plays an essential role in immune escape, cell proliferation and tumor angiogenesis, making it
Antão Chang
exaly +2 more sources
CD73 Activity is Dispensable for the Polarization of M2 Macrophages.
PLoS ONE, 2015 The ectoenzyme CD73 catalyzes the hydrolysis of AMP, and is one of the most important producers of extracellular adenosine. On regulatory T cells, CD73 is necessary for immunosuppressive functions, and on Th17 cells CD73-generated adenosine exerts anti ...
Dominik Eichin +3 more
doaj +2 more sources
CD73 promotes tumor growth and metastasis [PDF]
OncoImmunology, 2012 Our recent data and that of others demonstrate that both tumor and host CD73-generated adenosine promote tumor growth and metastasis in a multifactorial manner. Results with small molecule inhibitors or monoclonal antibodies against CD73 in multiple tumor models suggest that CD73 is a previously unappreciated important target for effective cancer ...
exaly +3 more sources